Table 3.
Vascular function variables at the start and end of the supplementation and placebo periods.
| SAx | Placebo | |||
|---|---|---|---|---|
| (n = 67) | (n = 67) | |||
| SBP | (mmHg) | Start | 111.3 ± 12.9 | 110.2 ± 13.3 |
| End | 101.9 ± 12.0 *** | 107.4 ± 14.8 | ||
| Change | −9.419 ± 10.3 # | −2.792 ± 11.2 | ||
| DBP | (mmHg) | Start | 74.34 ± 10.1 | 72.68 ± 10.1 |
| End | 71.60 ± 10.4 *** | 71.42 ± 9.7 | ||
| Change | −2.742 ± 8.4 | −1.258 ± 8.1 | ||
| HR | (bpm) | Start | 68.63 ± 10.7 | 69.13 ± 9.4 |
| End | 67.67 ± 9.8 | 67.88 ± 8.4 | ||
| Change | −0.962 ± 8.3 | −1.250 ± 9.1 | ||
| FMD | (%) | Start | 8.036 ± 4.0 | 8.077 ± 3.3 |
| End | 9.462 ± 4.0 * | 8.619 ± 4.0 | ||
| Change | 1.427 ± 3.7 | 0.542 ± 3.4 | ||
| sVCAM-1 | (pg/mL) | Start | 650.8 ± 192.9 | 635.3 ± 174.9 |
| End | 625.0 ± 163.9 | 588.7 ± 136.7 | ||
| Change | −25.84 ± 175.1 | −46.66 ± 126.6 |
Data are expressed as the means ± SDs. SAx: Oral Supplementation with HT and PC; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; HR: Heart Rate; FMD: Flow Mediated Dilatation; sVCAM-1: soluble Vascular Cell Adhesion Molecule-1. Significant differences between the start and end of the intervention periods (* p < 0.05, *** p < 0.001). Significant differences in the change recorded between the intervention periods (# p < 0.05).